BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 2749603)

  • 1. In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer.
    McCulloch P; Douglas J; Lowe GD; Murray G; George WD
    Thromb Haemost; 1989 Apr; 61(2):318-21. PubMed ID: 2749603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Activity of the coagulation and fibrinolysis in non-insulin-dependent diabetes mellitus. In vivo study].
    Conti M; Marongiu F; Mameli G; Mamusa AM; Cambuli AB; Cossu E; Sorano GG; Biondi G; Cirillo R; Balestrieri A
    Recenti Prog Med; 1989 Jun; 80(6):297-9. PubMed ID: 2772395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator.
    Ring ME; Butman SM; Bruck DC; Feinberg WM; Corrigan JJ
    Thromb Haemost; 1988 Dec; 60(3):428-33. PubMed ID: 2976994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline.
    Nossel HL; Wasser J; Kaplan KL; LaGamma KS; Yudelman I; Canfield RE
    J Clin Invest; 1979 Nov; 64(5):1371-8. PubMed ID: 500818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of fibrinopeptide A and fibrinopeptide B beta 15-42 in glomerulonephritis and the nephrotic syndrome.
    Tomura S; Oono Y; Kuriyama R; Takeuchi J
    Arch Intern Med; 1985 Jun; 145(6):1033-5. PubMed ID: 4004427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Coagulation-fibrinolysis abnormalities in acute stage of subarachnoid hemorrhage (Part 1)--With special reference to the relation between cerebral vasospasm and fibrinopeptides A and B beta].
    Touho H; Hino A; Suzuki K; Kubo T; Hirakawa K
    No To Shinkei; 1984 Oct; 36(10):1009-14. PubMed ID: 6518124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
    Koga S
    Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases].
    Murakoshi T
    Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blood coagulation and fibrinolysis in anesthesia and operations, with special reference to FPA, FPB beta 15-42].
    Gando S; Tedo I; Hanaoka Y; Makise N; Tsujinaga H; Kubota M
    Masui; 1988 Apr; 37(4):451-6. PubMed ID: 3398226
    [No Abstract]   [Full Text] [Related]  

  • 10. [Serial changes in FPA and FPB beta 15-42 during surgery with cardiopulmonary bypass].
    Gando S; Tedo I; Tsujinaga H; Kubota M
    Masui; 1988 May; 37(5):541-5. PubMed ID: 3411777
    [No Abstract]   [Full Text] [Related]  

  • 11. The action of Russell's viper venom on fibrin formation and fibrinolysis in vivo.
    Woodhams BJ; Than T; Than T; Hutton RA
    Br J Haematol; 1989 Jan; 71(1):107-11. PubMed ID: 2492816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinopeptide A and B beta 15-42 in liver cirrhosis.
    Marongiu F; Mameli G; Acca MR; Mulas G; Medda A; Tronci MB; Mamusa AM; Balestrieri A
    Haemostasis; 1988; 18(2):126-8. PubMed ID: 2457543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay.
    Marongiu F; Mamusa AM; Mameli G; Conti M; Sorano GG; Biondi G; Farci P; Balestrieri A
    Ric Clin Lab; 1989; 19(2):157-63. PubMed ID: 2528202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural considerations of plasmic degradation of fibrinogen.
    Marder VJ; Budzynski AZ
    Pathol Biol (Paris); 1974 Nov; 22 suppl():43-6. PubMed ID: 4283397
    [No Abstract]   [Full Text] [Related]  

  • 15. Levels of fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (FPB beta) in urine and plasma after urokinase administration in patients with chronic glomerulonephritis.
    Miura M; Tomino Y; Inoue W; Yagame M; Tamura S; Nomoto Y; Sakai H
    Tokai J Exp Clin Med; 1986 Oct; 11(4):273-7. PubMed ID: 3617111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of fibrinogen/fibrin degradation products (F/F DP)].
    Alakhverdian R
    Vutr Boles; 1979; 18(3):160-7. PubMed ID: 89851
    [No Abstract]   [Full Text] [Related]  

  • 17. [Coagulation-fibrinolysis abnormalities in acute stage hypertensive intra-cerebral hemorrhage and head injury (preliminary report). With special reference to fibrinopeptides A and B beta 15-42].
    Touho H; Hino A; Suzuki K; Kubo S; Hirakawa K
    Neurol Med Chir (Tokyo); 1985 Mar; 25(3):203-8. PubMed ID: 2409465
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
    Widström O; Kockum C; Nilsson BS
    Scand J Respir Dis; 1978 Aug; 59(4):210-5. PubMed ID: 694476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular markers of hemostatic mechanisms--fibrinopeptide B beta 1-42].
    Kuroso K
    Rinsho Byori; 1989 Mar; 37(3):234-9. PubMed ID: 2664279
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemostatic markers in acute stroke.
    Feinberg WM; Bruck DC; Ring ME; Corrigan JJ
    Stroke; 1989 May; 20(5):592-7. PubMed ID: 2718198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.